Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the cleantalk-spam-protect domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /wordpress/wp-includes/functions.php on line 6121 Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the divi-booster domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /wordpress/wp-includes/functions.php on line 6121 Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wpmudev domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /wordpress/wp-includes/functions.php on line 6121 FDA approves generic versions of ADHD drug Vyvanse | DeMarle, Inc.

FDA approves generic versions of ADHD drug Vyvanse

by | Jan 15, 2024 | ADHD, Attention Deficit Hyperactivity Disorder, Medicine, Other Health Impairment

The Food and Drug Administration (FDA) approved the first generic versions of Vyvanse, a drug used to treat attention deficit/hyperactivity disorder (ADHD), a decision that comes amid a nationwide shortage of ADHD treatment drugs. 

The newly approved medication can treat both ADHD in patients six years and older and binge-eating disorder in adults, the FDA said in an announcement.